Radiopharm sets FDA meeting for RAD101 brain metastases trial design

August 17, 2026 7:30 AM

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) has scheduled an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found